All In Biotech

Investigational drug · Phase 3

Vamikibart

Also called: RO7200220

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Uveitic Macular Edema.

Phase 3

Last checked: Nov 20, 2026Latest source record: Apr 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

0 still active

All registered trials

5

Any phase or sponsor naming "Vamikibart"

First trial start

2023

Jan 9, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Vamikibart", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Uveitic Macular Edema

Approved drugs for the same conditions: Ophthalmology

Largest trials

Live from ClinicalTrials.gov: studies naming "Vamikibart" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.